

Date: Jan 18, 2023

Invitation To Tender for CMC Service of IVD Monoclonal Antibody

Dear Sir/Madam,

You are invited to submit a tender to support Tiberias Technology Limited and its affiliates (**the Company**) to manufacture monoclonal antibody (mAb) for its IVD pipeline.

By participating in this tender, you are indicating your acceptance to be bound by the guidelines set out in this letter and attachments. We provide below the key details of requirements, which you should take into account in your response.

To simplify exchange of information regarding this Invitation to Tender (ITT) please nominate a Bid Manager (together with their deputy) and relevant contact telephone, facsimile numbers, and email addresses.

Please direct any questions regarding the ITT content or process to the Company's representatives named below. You should not contact other Tiberias Technology Ltd personnel unless directed to do so by Tiberias Technology Ltd representative. The Company reserves the right to disqualify and reject proposals from suppliers who do not comply with these guidelines. All questions should be submitted in writing either by post or to the email address below.

Only communications made by your Bid Manager (or their deputy) to our named representatives, Justin Lu, Project Director, will be considered during the pre-contact tender period.

As part of this tender process Tiberias Technology Ltd makes no obligations in any way to:

- i. pay any vendor for any ITT response; or
- ii. award the contract with the lowest or any bidder; or
- iii. accept any ITT information received from vendors; or
- iv. include vendors responding to this ITT, in any future invitation; or
- v. any other commitment to vendors whatsoever.

I look forward to receiving your response.

Yours sincerely,

Justin Lu
Project Director
Tiberias Technology Ltd
E: justin.lu@arbelebio.com
T: 852 98521265

Ref: T-23-02

Invitation To Tender

Invitation To Tender for CMC Service of IVD Monoclonal Antibody

A. Background

Tiberias Technology Limited, a sister company with Arbele Limited and a wholly owned subsidiary of Arbele Investment limited. The company is currently developing its IVD pipeline for medical device registration in China and United States. Tiberias needs to manufacture the company proprietary mAb antibodies to fulfill the pre-clinical validation, clinical studies and registration needs.

B. Project Summary

To initiate the IVD assay development, we are now seeking a proposal to support CMC service of IVD mAb manufacturing for Class III Medical Device registration in compliance with the regulations, policies, and guidelines pertinent to NMPA, FDA, EMA registration requirement. List and scope of services requirement are as follow:

Tiberias is seeking a CDMO that will provide support for the following tasks:

- Project management
- Materials and technology transfer
- Cell Banking
- Cell culture process development
- Purification process development
- IVD mAb buffer development
- Analytical method development and qualification
- Production for IVD mAb
- Stability study for IVD mAb
- Regulatory support for CMC of IVD mAb

C. Respondent Instruction

For more information and inquires, interested parties and manufacturer may contact us at any office hours. Tenders should be submitted ASAP, but no later than 18:00 Hong Kong time on 28th of February 2023. Submitted proposals will be reviewed immediately and bid defense meeting will be organized once multiple tender proposals received. Award of notice will be issued in mid-late March 2023. Please deliver an electronic copy of the written proposal with pricing information to:

Mr. Justin Lu, Project Director. E: justin.lu@arbelebio.com

Tiberias Ltd reserves the right to disregard any response submitted after the deadline, and to modify the provisions of this ITT at any time prior to the scheduled date for written responses. Additional scope and requirements can be added. Notification of such changes will be provided to all vendors.

It is requested that all activities listed in Part B be addressed in your proposal (including services that you do not provide). Further items, also need to be addressed in the proposal are:

- Organization chart
- Gantt Chart
- Budget
- Summary of the team's experience

D. Evaluation criteria

Fulfilment of the below criteria is compulsory. The service provider should:

- demonstrate regulatory capability for assisting pharmaceutical and biotechnology company.
- have extensive experience in handling similar projects in terms of mAb production.

If the service providers pass criterion no.1, the responses will be assessed using the following criteria and weightings (% ratio):

- The price should be competitive with reasonable payment terms (30%)
- The service provider shows a good track record for the similar production project (30%)
- The project deliverables timeline, milestones will also be considered (30%)
- Experience of the project leads and functional team (10%)

The procurement contract will be awarded to the service provider with the highest assessment scores.